DFDA

Methotrexate

Treatment for Interstitial Lung Disease And Pulmonary Sarcoidosis

Typical Dosage: 10-25 mg once weekly

Effectiveness
58%
Safety Score
30%
Clinical Trials
2
Participants
4K

Comparative Safety Scale(Higher is safer)

Cyanide☠ī¸
Meth💀
CigarettesđŸšŦ
Chemoâ˜ĸī¸
AlcoholđŸē
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
10-25 mg once weekly
Time to Effect
2-3 months
Treatment Duration
1-2 years (or longer)
Evidence Quality
MODERATE
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$750
Side Effect Mgmt:$300
Total Annual:$1,250
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
Outcome-Based Costs
Cost per Responder
$2,083
Cost per Remission
$4,167
Methotrexate Outcomes

for Interstitial Lung Disease And Pulmonary Sarcoidosis

Efficacy Outcomes
Overall Effectiveness
+58%
Response Rate
+60%
Remission Rate
+30%
Common Side Effects
Nausea
+25%
Fatigue
+15%
Liver enzyme elevation
+15%
Oral ulcers
+8%
Myelosuppression (rare)
+2%

Sources:

nih.gov
sarcoidosisnews.com
respiratory-therapy.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov